We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+9.41%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$1.08B
(+126%)
Cap. Flow
+$347M
Cap. Flow
% of AUM
17.97%
Top 10 Holdings %
Top 10 Hldgs %
58.78%
Holding
104
New
42
Increased
25
Reduced
17
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARK Genomic Revolution ETF
ARKG
|
+$80M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$31.3M |
| 3 |
OCDX
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
|
+$24.2M |
| 4 |
Community Health Systems
CYH
|
+$23.5M |
| 5 |
McKesson
MCK
|
+$22.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$23.6M |
| 2 |
The Ensign Group
ENSG
|
+$15.4M |
| 3 |
CTLT
CATALENT, INC.
CTLT
|
+$13M |
| 4 |
HSKA
Heska Corp
HSKA
|
+$11.5M |
| 5 |
RAD
Rite Aid Corporation
RAD
|
+$10.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.91% |
| 2 | Miscellaneous | 40.99% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OTIC
1
CALL
DELISTED
Otonomy, Inc.
OTIC
| $506M | 26.21% |
+198,400
| New | +$813K |
|
|
AMRN
2
Amarin Corp
AMRN
$295M
| $105M | 5.44% |
844,840
+47,644
| +6% | +$6.41M |
|
3
CALL
Korro Bio
KRRO
$190M
| $94.8M | 4.91% |
+200
| New | +$389K |
|
4
United Therapeutics
UTHR
$22.1B
| $81.4M | 4.22% |
486,529
+27,893
| +6% | +$4.65M |
|
|
5
ARK Genomic Revolution ETF
ARKG
$1.88B
| $71.6M | 3.71% |
+806,932
| New | +$80M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $71.3M | 3.69% |
465,983
+89,783
| +24% | +$13.9M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $64M | 3.32% |
695,459
+164,483
| +31% | +$13.9M |
|
8
Teva Pharmaceuticals
TEVA
$42.5B
| $50.3M | 2.6% |
4,354,756
+1,606,506
| +58% | +$18.4M |
|
9
AstraZeneca
AZN
$252B
| $49.3M | 2.56% |
496,158
+69,942
| +16% | +$7.03M |
|
10
CALL
GSK
GSK
$102B
| $41.2M | 2.13% |
923,280
+641,200
| +227% | +$29.1M |
|
11
Ascendis Pharma A/S
ASND
$16.3B
| $40.2M | 2.08% |
311,867
+124,824
| +67% | +$19M |
|
12
Danaher
DHR
$152B
| $40M | 2.07% |
200,258
+57,758
| +41% | +$11.7M |
|
13
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
| $39.6M | 2.05% |
+100,000
| New | +$38.6M |
|
14
TG Therapeutics
TGTX
$8.26B
| $36.8M | 1.9% |
762,589
-101,262
| -12% | -$4.87M |
|
|
XLRN
15
DELISTED
Acceleron Pharma
XLRN
| $32.8M | 1.7% |
+241,981
| New | +$31.3M |
|
|
16
Community Health Systems
CYH
$413M
| $32.5M | 1.69% |
2,405,834
+2,393,029
| +18,688% | +$23.5M |
|
17
Amneal Pharmaceuticals
AMRX
$6.11B
| $32M | 1.66% |
4,755,480
+3,577,327
| +304% | +$19.8M |
|
|
18
GSK
GSK
$102B
| $31.1M | 1.61% |
681,765
-75,500
| -10% | -$3.43M |
|
19
Envista
NVST
$4.36B
| $29.9M | 1.55% |
732,684
-128,671
| -15% | -$4.9M |
|
20
Avantor
AVTR
$9.86B
| $27.7M | 1.44% |
958,987
+38,337
| +4% | +$1.11M |
|
|
OCDX
21
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $26.5M | 1.37% |
+1,375,228
| New | +$24.2M |
|
22
Fate Therapeutics
FATE
$291M
| $26.5M | 1.37% |
321,760
-77,739
| -19% | -$7.45M |
|
|
23
McKesson
MCK
$104B
| $24M | 1.24% |
+122,983
| New | +$22.4M |
|
24
Elevance Health
ELV
$85.5B
| $22.9M | 1.19% |
63,892
-1,879
| -3% | -$604K |
|
25
Qiagen
QGEN
$8.9B
| $22.1M | 1.15% |
428,827
+111,147
| +35% | +$6.11M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Eversept Partners held 104 positions worth $1.93B, up 126% from $852M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Eversept Partners deployed $347M of net new capital in Q1 2021, opening 42 new positions and adding to 25 existing holdings. Its largest new stake was ARK Genomic Revolution ETF: 806,932 shares worth $71.6M.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
On the sell side, the largest reduction was The Ensign Group, an estimated $15.4M trimmed.
- Eversept Partners's largest Q1 2021 buy was ARK Genomic Revolution ETF: 806,932 shares worth $71.6M.
- Eversept Partners added most to Community Health Systems in Q1 2021, an estimated $23.5M increase.
- Eversept Partners's biggest Q1 2021 reduction was The Ensign Group, cutting an estimated $15.4M.
- Eversept Partners fully exited Sarepta Therapeutics in Q1 2021, selling an estimated $23.6M.
- Eversept Partners's ten largest holdings make up 59% of its $1.93B portfolio in Q1 2021.
- Eversept Partners opened 42 new positions and closed 19 in Q1 2021.
- Eversept Partners's portfolio value rose 126% quarter-over-quarter to $1.93B.
Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.